Stockscreener 앱 받기
6.49
4.70%
-0.32
시간 외 거래:
6.49
전일 마감가:
$6.81
열려 있는:
$6.86
하루 거래량:
411.91K
Relative Volume:
0.57
시가총액:
$351.05M
수익:
$2.81M
순이익/손실:
$-97.34M
주가수익비율:
-4.1076
EPS:
-1.58
순현금흐름:
$-91.47M
1주 성능:
-4.98%
1개월 성능:
-17.32%
6개월 성능:
+75.88%
1년 성능:
-27.49%
1일 변동 폭
$6.47
$6.88
1주일 범위
$6.47
$7.03
52주 변동 폭
$2.315
$10.13
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
명칭
Fulcrum Therapeutics Inc
전화
617-651-8851
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
FULC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
6.49 | 375.40M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-29 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-09-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-09-09 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2023-09-25 | 개시 | Goldman | Neutral |
| 2023-08-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | 업그레이드 | Stifel | Hold → Buy |
| 2023-05-04 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-02-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 개시 | Goldman | Buy |
| 2022-03-08 | 개시 | Oppenheimer | Outperform |
| 2022-03-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-08-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2020-10-16 | 개시 | Piper Sandler | Overweight |
| 2020-08-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2019-10-03 | 개시 | H.C. Wainwright | Buy |
| 2019-08-12 | 개시 | BofA/Merrill | Buy |
모두보기
Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스
How high can Fulcrum Therapeutics Inc. stock goShort Term Profit Strategy with Entry Cues - Newser
Why Fulcrum Therapeutics Inc. stock attracts strong analyst attentionWeekly Market Direction and Sector Summary - Newser
Is Fulcrum Therapeutics Inc. meeting your algorithmic filter criteriaFree Consistent Profit Pattern Recognition Tools - Newser
What recovery options are there for Fulcrum Therapeutics Inc.Retirement Investment Outlook and Return Summary - Newser
When is the best time to exit Fulcrum Therapeutics Inc.Real Time Stock Movement and Alerts - Newser
Does Fulcrum Therapeutics Inc. qualify in momentum factor screeningSwing Candidate List with Trade Cues - Newser
Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - The Globe and Mail
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Comparing Fulcrum Therapeutics Inc. in custom built stock radarsFree Capital Efficiency Optimized Stock Alerts - Newser
Is Fulcrum Therapeutics Inc. stock ready for a breakoutLow Volatility Stock Analysis With Confidence - Newser
Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Lowered by Wall Street Zen - Defense World
Published on: 2025-08-09 00:54:39 - Newser
Forecasting Fulcrum Therapeutics Inc. price range with options dataFree Stock Portfolio Allocation Guidance - Newser
Is Fulcrum Therapeutics Inc. a Top Dividend Stock to Watch in 2025Short-Term Market Movement Forecast Report - Newser
Fulcrum Therapeutics Awards $6.96 Stock Options Package: 4-Year Vesting Terms Revealed - Stock Titan
Real time pattern detection on Fulcrum Therapeutics Inc. stockPredicted Market Direction Based on Momentum - Newser
Quant Models Detect Momentum Reversal in Fulcrum Therapeutics Inc.Low Volatility Stable Growth Picks Rank High - beatles.ru
Fulcrum defended at H.C. Wainwright after data for sickle cell disease drug - MSN
Chart overlay techniques for tracking Fulcrum Therapeutics Inc.Free Long Hold Safe Return Strategy - Newser
Fulcrum Therapeutics Reports Q2 2025 Financial Results - TipRanks
Technical Bounce Expected in Fulcrum Therapeutics Inc. Next WeekAI Based High Gain Watchlist Scanner Shared - beatles.ru
Strategy Insiders Buy In While Analysts Predict Big Upside - The Globe and Mail
Applying big data sentiment scoring on Fulcrum Therapeutics Inc.Buy Alert Based on RSI and Volume - Newser
Technical signs of recovery in Fulcrum Therapeutics Inc.AI Entry Timing Prediction for Swing Traders - Newser
Fulcrum Therapeutics Inc. Stock Analysis and ForecastAchieve breakthrough gains with smart trades - Jammu Links News
What catalysts could drive Fulcrum Therapeutics Inc. stock higher in 2025Build wealth with long-term growth strategies - Jammu Links News
What are analysts’ price targets for Fulcrum Therapeutics Inc. in the next 12 monthsBuild a portfolio that stands the test of time - Jammu Links News
Why is Fulcrum Therapeutics Inc. stock attracting strong analyst attentionMassive stock growth - Jammu Links News
Is Fulcrum Therapeutics Inc. a good long term investmentUnlock powerful trading strategies for gains - Jammu Links News
What is the risk reward ratio of investing in Fulcrum Therapeutics Inc. stockBuild a winning investment strategy today - Jammu Links News
What analysts say about Fulcrum Therapeutics Inc. stockAchieve impressive returns with smart timing - Jammu Links News
What is Fulcrum Therapeutics Inc. company’s growth strategyUnlock powerful market insights for success - Jammu Links News
Fulcrum Therapeutics shares slide 17% after sickle cell trial results - MSN
When is Fulcrum Therapeutics Inc. stock expected to show significant growthFree Market Dynamics Reports - jammulinksnews.com
How strong is Fulcrum Therapeutics Inc. company’s balance sheetMaximize returns with timely market signals - Jammu Links News
How does Fulcrum Therapeutics Inc. generate profit in a changing economyHigh-profit capital plays - Jammu Links News
What institutional investors are buying Fulcrum Therapeutics Inc. stockInvest smarter with cutting-edge analytics - jammulinksnews.com
Is Fulcrum Therapeutics Inc. stock overvalued or undervaluedAccess exclusive market insights for free - Jammu Links News
FY2025 EPS Estimates for FULC Raised by Cantor Fitzgerald - Defense World
Will Fulcrum Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsOversold Opportunity Scanner with RSI Data - Newser
Q3 Earnings Forecast for FULC Issued By Leerink Partnrs - Defense World
Are Bears Losing Grip on Fulcrum Therapeutics Inc.Reliable Investment Entry Signals Confirmed by Charts - metal.it
How to interpret RSI for Fulcrum Therapeutics Inc. stockTen-Year Sector Performance and Summary Analysis - Newser
Fulcrum Therapeutics Inc (FULC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):